Tesamorelin Before and After: The Numbers the Trials Recorded

01Quick Answer

What Tesamorelin Before and After Looks Like in the Trials

Tesamorelin before and after, as the trials recorded it, looks like deep abdominal fat falling while body weight barely moves. In the pivotal 26-week trial, visceral adipose tissue fell 15.2% in the tesamorelin group and rose 5.0% in the placebo group, in 412 adults with HIV who had accumulated abdominal fat on antiretroviral therapy (Falutz and colleagues, New England Journal of Medicine, 2007, PMID 18057338).

That is the whole shape of the result, and it is narrower than the before-and-after galleries suggest. The fat that moved was visceral, the fat behind the abdominal wall and around the organs. The fat a camera photographs is subcutaneous, and in the pooled phase 3 analysis it changed by a treatment effect of 0.6%, a difference that did not reach significance (Falutz and colleagues, Journal of Clinical Endocrinology and Metabolism, 2010, PMID 20554713).

• Week 26. Visceral fat 15.2% down against a 5.0% rise on placebo; triglycerides down 50 mg/dL.
• Week 52. Visceral fat 17.5% below baseline; waist circumference 3.4 cm smaller.
• Subcutaneous fat. Preserved, not reduced. Treatment effect 0.6%, p=0.08.
• Body weight. The FDA label calls the drug weight neutral and says it is not indicated for weight loss management.
• After stopping. Visceral fat reaccumulated.

So a fair tesamorelin before and after is a waistline and a scan result rather than a silhouette, and the rest of this page is the detail behind those five lines.

02Disclosure

Commercial Interest, Stated Up Front

Our commercial interest is stated up front: Protocol Health prescribes tesamorelin, so this page is written by a clinic that stands to gain if you ask for it. Saying so changes nothing about the numbers below, which come from the published trials and the FDA label rather than from our own patients.

Tesamorelin is sold as tesamorelin therapy at Protocol Health under clinician supervision, and a prescription follows labs and a history rather than a photograph. Pricing depends on your plan, and a consultation is the first step. Nothing on this page is a dosing instruction, and no schedule, chart or calculator appears anywhere in it.

03The Population

Tesamorelin Before and After in Men and Women: Who the Trials Enrolled

Tesamorelin before and after data in men and women comes from trials that enrolled adults with HIV on antiretroviral therapy who had excess abdominal fat, and nobody else. The 2007 trial randomized 412 such patients, 86% of them men, to 2 mg of tesamorelin or placebo by daily subcutaneous injection for 26 weeks (PMID 18057338). The pooled phase 3 analysis combined two trials of the same design into 806 patients, 543 on tesamorelin and 263 on placebo (PMID 20554713).

That population matters more than any single percentage on this page. Visceral fat accumulation on antiretroviral therapy is a specific metabolic problem, and the people who have it are not a random sample of adults who want a flatter stomach. A result measured in them is evidence about them, and an extrapolation about anyone else.

The before-and-after images circulating under this search term almost never come from that population. They come from off-label use of compounded tesamorelin in people who were never studied, which is a different product given to a different group for a different reason. Tesamorelin before and after men and tesamorelin before and after women are both reasonable questions to ask, and the honest answer for either is that the trials were 86% male and entirely within one diagnosis.

04The Timeline

The Tesamorelin Before and After Timeline, Week by Week

The tesamorelin before and after timeline has exactly two measured checkpoints, week 26 and week 52, because those are the only points the trials reported. Competing timelines that promise a change at week 2 and a visible waistline at week 6 are filling in the gaps between those two checkpoints with narrative.

Weeks 1 to 12: No Measured Checkpoint

Weeks 1 to 12 carry no measured checkpoint for body composition in the tesamorelin record. What the trials did measure is hormonal rather than visible, though it too was reported at week 26: insulin-like growth factor 1 rose 81.0% in the tesamorelin group against a 5.0% fall on placebo over the 26-week trial, and by a mean of 108 ng/mL in the pooled analysis (PMID 18057338; PMID 20554713). A blood marker moving is not a before and after, and a tesamorelin before and after 1 month claim has no trial checkpoint behind it.

Week 26: Visceral Fat Down 15.2%

Week 26 is the first measured checkpoint, and visceral fat was down 15.2% on tesamorelin against a 5.0% rise on placebo. In absolute terms the pooled analysis recorded a change of 24 cm² lost on tesamorelin against 2 cm² gained on placebo, a treatment effect of 15.4% (PMID 20554713). Triglycerides fell 50 mg/dL in the 2007 trial while rising 9 mg/dL on placebo, and the ratio of total cholesterol to HDL cholesterol fell 0.31 while rising 0.21 on placebo (PMID 18057338).

Patients also rated their own midsection differently at that point. Belly appearance distress improved with p=0.002, patient rating of belly profile with p=0.003, and physician rating of belly profile with p<0.001 (PMID 20554713). Those are the closest thing in the record to a before-and-after judgement, and they were collected as rating scales rather than photographs.

Week 52: Visceral Fat Down 17.5%, Waist Down 3.4 cm

Week 52 held visceral fat 17.5% below baseline and waist circumference 3.4 cm below it, in the group that stayed on tesamorelin for the full year. The absolute visceral fat change was 35 cm², triglycerides were 48 mg/dL lower and total cholesterol 8 mg/dL lower, all against original baseline (PMID 20554713). The separate 52-week safety report put the sustained visceral fat change at 18% (Falutz and colleagues, AIDS, 2008, PMID 18690162).

A tesamorelin timeline built from that table runs in months and in centimetres, which is why tesamorelin before and after 3 months sits between the two checkpoints rather than on one.

05What Photos Miss

Why a Tesamorelin Before and After Photo Misses the Result

A tesamorelin before and after photo misses the result because the fat that moved sits too deep for a camera to reach. Visceral adipose tissue lies behind the abdominal wall, around the liver and intestines, and it was measured in every one of these trials by computed tomography rather than by eye.

The layer a photograph does show is abdominal subcutaneous fat, and that layer was the one the trials found largely preserved. The pooled analysis recorded 2 cm² lost on tesamorelin against 2 cm² gained on placebo, p=0.08, a treatment effect of 0.6% (PMID 20554713). The pooled analysis reported this as preservation of subcutaneous fat, which matters in this population because losing it is part of the lipodystrophy problem, because losing it is part of the lipodystrophy problem rather than part of the solution.

• Wrong layer. The camera reads subcutaneous fat; the drug moved visceral fat.
• Wrong instrument. The endpoint was a CT cross-section in square centimetres, not an image.
• No denominator. Clinics publish the people it worked for, never the number it was tried on.
• No control. Training, food and sleep usually change in the same months, and no photograph separates them.
• Posture and light. Both move an abdominal silhouette further in one afternoon than 3.4 cm of waist did in a year.

Tesamorelin before and after pictures and tesamorelin before and after photos are therefore asking the record for proof it does not contain, and the record answers in square centimetres instead.

06The Spread

How Much Do Tesamorelin Results Vary?

Tesamorelin results vary widely, and on this drug the spread around the average is as large as the average itself. Visceral fat at week 52 was reported as 17.5% below baseline with a standard deviation of 23.3%, and waist circumference as 3.4 cm smaller with a standard deviation of 6.0 cm (PMID 20554713).

A standard deviation larger than the mean has a plain reading. A meaningful share of patients in that trial lost far more visceral fat than the headline figure, and another meaningful share lost none or gained some. The same arithmetic applies to the waist: 3.4 cm plus or minus 6.0 cm includes people whose waist was unchanged after a year of daily injections.

The FDA wrote that possibility into the label rather than leaving it to inference. The Limitations of Use section of the EGRIFTA WR prescribing information tells clinicians to consider the risk and benefit of continuing treatment in patients who have not had a reduction in visceral adipose tissue (EGRIFTA WR prescribing information, DailyMed). A regulator only writes a non-response clause when non-response is expected.

07Risks

Tesamorelin Risks and Side Effects, Given Equal Weight

Tesamorelin risks and side effects deserve equal weight on an outcomes page, because the prescribing information records several that no before-and-after image would ever show. The EGRIFTA WR label lists the most common adverse reactions above 5% as arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema and myalgia (DailyMed, linked above).

• Neoplasms. The label warns that the drug induces release of growth hormone, a known growth factor. Patients with active malignancy must not take it, and treatment is stopped on any evidence of recurrent malignancy.
• Elevated IGF-1. IGF-1 rose 81.0% in the 26-week trial and by a mean of 108 ng/mL in the pooled analysis. The label says the effects of prolonged elevation are unknown, instructs prescribers to monitor IGF-1 and to consider stopping on persistent elevation.
• Fluid retention. Edema, joint pain and carpal tunnel syndrome are described on the label as related to induced growth hormone secretion.
• Glucose intolerance or diabetes. Evaluate glucose before starting and monitor during therapy. The size of this signal is in the next section.
• Hypersensitivity. Rash and urticaria occurred in the clinical trials; the label tells patients to seek immediate attention and stop treatment if a reaction is suspected.
• Injection site reactions. Erythema, pruritus, pain, swelling, irritation and bleeding at the site, and the 2019 liver trial reported more localized injection site complaints on tesamorelin than on placebo.

The contraindications are worth reading in the same breath as any result. The label contraindicates tesamorelin in pregnancy, in active malignancy, in known hypersensitivity, and in patients whose hypothalamic-pituitary axis has been disrupted by surgery, a pituitary tumor, head irradiation or head trauma. It also tells prescribers to consider stopping in critically ill patients.

In the 2007 trial, adverse events did not differ significantly between the two groups overall, and yet more patients on tesamorelin withdrew from the study because of an adverse event (PMID 18057338). Both halves of that sentence belong on a page about results.

08The Glucose Question

Does Tesamorelin Raise Blood Sugar?

Tesamorelin can raise blood sugar in some patients: the trial summaries report no clinically meaningful change in group averages, while the FDA label reports roughly tripled odds of developing diabetes. Both statements describe the same patients, and the difference is in what each chose to count.

The published conclusions are consistent with each other. The 2007 trial found no significant differences in glycemic measures at 26 weeks (PMID 18057338). The pooled analysis found no clinically meaningful differences between groups in glucose parameters at weeks 26 and 52 (PMID 20554713). The 52-week safety report concluded that changes in glucose parameters over a year were not clinically significant (PMID 18690162). The 2019 liver trial found no difference in fasting glucose or glycated hemoglobin at 12 months (Stanley and colleagues, Lancet HIV, 2019, PMID 31611038).

The label counts something narrower and arrives somewhere sharper. It reports that the percentage of patients with HbA1c at or above 6.5% from baseline to week 26 was 5% on EGRIFTA and 1% on placebo, and gives an intent-to-treat odds ratio of 3.3, with a confidence interval of 1.4 to 9.6, for developing diabetes relative to placebo (DailyMed, linked above). A group mean that does not move can still hide a small number of people crossing a diagnostic threshold.

Protocol Health treats the stricter reading as the operative one. Glucose status is checked before any prescription and monitored during treatment, which is what the label instructs and what the odds ratio justifies.

09Stopping

What Happens to Tesamorelin Results After Stopping

Tesamorelin results reverse after stopping, and the trial that tested it said so without hedging. In the 52-week extension, patients originally on tesamorelin were re-randomized at week 26, and in the group switched to placebo the visceral fat reaccumulated. The authors concluded that the effects on visceral fat do not last beyond the duration of treatment (PMID 18690162).

That single finding reframes every before-and-after image on this topic. A photograph taken at week 26 is a photograph of a state that requires a daily injection to hold. It is not a record of a change that has been banked, and nothing in the published record suggests a course of treatment followed by a durable result.

The practical consequence is that the decision is about indefinite treatment rather than a cycle, and that is a different conversation about cost, labs, adherence and risk tolerance. A clinician who presents tesamorelin as a finite protocol with a lasting outcome is describing something the extension phase measured and did not find.

10Regulatory Status

Is Tesamorelin FDA-Approved for Fat Loss?

Tesamorelin is FDA-approved for one use, and fat loss in the general sense is not it. The approved product, sold as EGRIFTA, is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and the label's Limitations of Use state that it is not indicated for weight loss management because it has a weight neutral effect (DailyMed, linked above). The same section records that long-term cardiovascular safety has not been established.

Compounded tesamorelin is a different matter again. It is not an FDA-approved product, it was not the material tested in any trial on this page, and its strength and purity are not verified by the agency. Anything prescribed outside the HIV-lipodystrophy indication is off-label use, which is lawful and routine in medicine and is not the same as an approved use.

One nearby compound deserves its own line, because tesamorelin ipamorelin before and after is a real search and the two are often blended. The FDA placed ipamorelin acetate in Category 2 under its 503B interim policy on September 29, 2023, the tier for bulk substances that may present significant safety risks, citing immunogenicity risk for certain routes of administration (FDA, certain bulk drug substances that may present significant safety risks). No trial has measured the blend, and ipamorelin at Protocol Health is prescribed, where appropriate, as an unapproved compounded peptide with that status disclosed.

For the background on the molecule itself, our guide to what tesamorelin is and what it does covers mechanism and candidacy, and sermorelin versus tesamorelin compares the two growth hormone-releasing analogs on their published evidence.

11Our Approach

Tesamorelin Before and After at Protocol Health

Protocol Health reads a tesamorelin before and after question by starting with labs and with the population the trials studied, rather than with a photograph. A physician reviews your history, orders baseline bloodwork including glucose, and decides whether tesamorelin, another peptide, or neither is appropriate.

What we will tell you at that visit is the content of this page. The measured result is visceral, the spread around it is wide, the subcutaneous layer does not change, the effect needs continued treatment to hold, and the label carries warnings about malignancy, IGF-1, fluid retention and glucose. If that set of facts does not match what you were hoping for, the right answer may be a different treatment or none.

Care is in person at our Scarsdale, NY clinic at 700 White Plains Rd, and by telehealth in NY, NJ, CT, FL and CA. Protocol Health is physician-led and family-owned. Pricing depends on your plan, and a consultation is the first step toward knowing whether tesamorelin belongs in it at all. Read the tesamorelin treatment page or take the Protocol Health quiz to start.

FAQ

Frequently Asked Questions

Explore

Related at Protocol Health

• Tesamorelin Therapy →
• What Is Tesamorelin? →
• Sermorelin vs Tesamorelin →
• Peptide Therapy →